TGFB1 and Hepatic fibrosis: Our data suggest that miR-497 promotes liver fibrogenesis by targeting Smad7 to modulate the TGF-β/Smad signaling pathway both in vivo and in vitro, which suggests that anti-miR-497 treatment represents a promising therapeutic strategy in liver fibrosis.